The resurgence of the SARS-Cov-2 infections makes even more urgent the quest for vaccines and therapies. After less than one year from the outbreak of the Covid-19 pandemic, almost 700 vaccines are under study worldwide and about 30 are at least in Phase III of clinical trials, a very advanced stage in such a short time. The aim of this event is to give an update on the situation in Italy and Japan in the field of Covid-19 vaccines and therapies, thus verifying the possibility of collaborations and synergies between the two countries.
VENUE: Online on Zoom
REGISTRATION: Click here
DATE AND TIME: 9 December 2020, 17.00-19.00 JST (9.00-11.00 CET)
17.00-17.08 Welcome and Opening Remarks – H.E. Giorgio Starace (Ambassador of Italy to Japan)
17.08-17.10 Introduction by the Moderator – Prof. Enrico Traversa (Scientific Counsellor, Embassy of Italy)
17.10-17.30 Japan Keynote on Vaccines – Prof. Ryuichi Morishita, Graduate School of Medicine, Osaka University, collaborating with AnGes on clinical trials
17.30-17.50 Italy Keynote on Vaccines – Dr. Alessandra Vitelli, ReiThera, Italian company developing a vaccine in Phase I (currently tested at Ospedale Spallanzani)
17.50-18.10 Japan Keynote on Therapies – Dr. Koichi Watashi, Senior Researcher, Department of Virology II, National Institute of Infectious Diseases
18.10-18.30 Italy Keynote on Therapies – Dr. Rino Rappuoli, GSK Vaccines, developing therapy based on monoclonal antibodies
18.30-19.00 Panel Discussion and Closing Remarks
Joint venture established in 1987 by the European Commission (DG GROW) and the Japanese Government (METI) for promoting all forms of industrial, trade and investment cooperation between the EU and Japan.